Valerio Therapeutics SA

Valerio Therapeutics operates with a negative equity position of EUR -8.93 million and a current ratio of 0.25, indicating significant liquidity constraints. The company's market capitalization is EUR 26.24 million, with a negative EV/EBITDA of -1.39 and an EV/Revenue of 18.45, both of which are unfavorable compared to industry norms. The company's cash and equivalents amount to EUR 1.18 million, while its long-term debt stands at EUR 8.03 million. The company's profitability is challenged, with a net loss of EUR 23.92 million and an operating loss of EUR 23.73 million. Its return on equity is 2.68%, which is positive but modest, while its return on assets is -1.33%, indicating poor asset utilization. The debt-to-equity ratio is -0.9, suggesting a high reliance on debt financing in a negative equity context. Valerio Therapeutics' revenue is concentrated in a few products, with Beleodaq, Loramyc, and Sitavig being the primary contributors. The company's geographic exposure is primarily in the United States and Europe, with no significant diversification into other regions. The company's revenue of EUR 1.79 million is modest, and its growth trajectory is uncertain given the current financial position. The company's outlook for the current fiscal year is negative, with a net loss expected to continue. The next fiscal year is projected to show a similar trend, with no significant improvement in revenue or profitability. The company's capital expenditures are minimal, with a negative value of EUR -0.32 million, indicating a lack of investment in growth. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key financial flag is the negative net cash position after subtracting total debt, which suggests a high risk of insolvency. The company's dilution potential is low, but the negative equity position could lead to further dilution if the company requires additional financing. Recent events include the continued development of Livatag and Validive, with no significant new product launches or regulatory approvals reported. The company's recent financial filings indicate ongoing losses and a lack of positive momentum in its financial performance.